Evaluating the impact of pharmacists in outpatient mental health settings: a systematic review.

IF 3.2 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Muireann Vaughan, Maria Donovan, Stephen Byrne, Fulvio Bedani, Sinéad O'Brien, Ciaran Halleran, Laura J Sahm
{"title":"Evaluating the impact of pharmacists in outpatient mental health settings: a systematic review.","authors":"Muireann Vaughan, Maria Donovan, Stephen Byrne, Fulvio Bedani, Sinéad O'Brien, Ciaran Halleran, Laura J Sahm","doi":"10.1007/s11096-026-02135-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mental disorders are estimated to affect one in seven people globally and are often linked to premature mortality. Psychotropic medicines play an important role in the management of many mental health conditions particularly where symptoms are moderate to severe, persistent, or complex. Pharmacists are increasingly recognised as key members of multidisciplinary mental health teams, with their role focusing on safe and effective use of psychotropic medicines. Mental healthcare is increasingly delivered in outpatient settings, however, the impact of pharmacists on these services remains underexplored.</p><p><strong>Aim: </strong>To systematically review and evaluate the impact of pharmacist-led or pharmacist-involved interventions specifically within outpatient mental health settings globally, across the full spectrum of mental disorders.</p><p><strong>Method: </strong>A systematic search of five electronic databases (MEDLINE, Embase, CINAHL, CENTRAL, and PsycINFO) was conducted from inception to October 2025. Grey literature sources including ClinicalTrials.gov and Google Scholar were also searched. Inclusion criteria were: (i) evaluation of a pharmacist-led or pharmacist-involved intervention with a measurable outcome; (ii) conducted in an outpatient mental health setting involving adults with a diagnosed mental disorder classified according to ICD (up to and including ICD-11) or DSM criteria (up to and including DSM-5), excluding dementia; and (iii) inclusion of a comparator or control group. Study screening, data extraction, and quality appraisal, were performed independently by two reviewers. Due to heterogeneity in study design and outcomes, a narrative synthesis was conducted.</p><p><strong>Results: </strong>Twenty-three studies met the inclusion criteria: 11 randomised controlled trials and 12 non-randomised studies. Pharmacist interventions varied, but most commonly included medication reviews, psychoeducation, adherence support and monitoring for side effects or drug interactions. Outcomes were grouped into seven domains: patient-reported, symptom-related, treatment-related, medication adherence, cost, monitoring and hospitalisations. Pharmacist impact was associated with improvements across multiple domains, particularly in medication adherence, treatment-related and symptom-related outcomes. While outcome measures varied between studies, a majority (82.6%) reported positive trends in at least one domain, favouring pharmacist-led or pharmacist-involved care over usual care.</p><p><strong>Conclusion: </strong>Pharmacist-led interventions in outpatient mental health settings are associated with positive clinical and healthcare-related outcomes across a range of mental disorders globally. These findings support the integration of pharmacists into multidisciplinary outpatient mental health teams and highlight the need for more high-quality, standardised research to inform service development and policy.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1197-1213"},"PeriodicalIF":3.2000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13369247/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-026-02135-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Mental disorders are estimated to affect one in seven people globally and are often linked to premature mortality. Psychotropic medicines play an important role in the management of many mental health conditions particularly where symptoms are moderate to severe, persistent, or complex. Pharmacists are increasingly recognised as key members of multidisciplinary mental health teams, with their role focusing on safe and effective use of psychotropic medicines. Mental healthcare is increasingly delivered in outpatient settings, however, the impact of pharmacists on these services remains underexplored.

Aim: To systematically review and evaluate the impact of pharmacist-led or pharmacist-involved interventions specifically within outpatient mental health settings globally, across the full spectrum of mental disorders.

Method: A systematic search of five electronic databases (MEDLINE, Embase, CINAHL, CENTRAL, and PsycINFO) was conducted from inception to October 2025. Grey literature sources including ClinicalTrials.gov and Google Scholar were also searched. Inclusion criteria were: (i) evaluation of a pharmacist-led or pharmacist-involved intervention with a measurable outcome; (ii) conducted in an outpatient mental health setting involving adults with a diagnosed mental disorder classified according to ICD (up to and including ICD-11) or DSM criteria (up to and including DSM-5), excluding dementia; and (iii) inclusion of a comparator or control group. Study screening, data extraction, and quality appraisal, were performed independently by two reviewers. Due to heterogeneity in study design and outcomes, a narrative synthesis was conducted.

Results: Twenty-three studies met the inclusion criteria: 11 randomised controlled trials and 12 non-randomised studies. Pharmacist interventions varied, but most commonly included medication reviews, psychoeducation, adherence support and monitoring for side effects or drug interactions. Outcomes were grouped into seven domains: patient-reported, symptom-related, treatment-related, medication adherence, cost, monitoring and hospitalisations. Pharmacist impact was associated with improvements across multiple domains, particularly in medication adherence, treatment-related and symptom-related outcomes. While outcome measures varied between studies, a majority (82.6%) reported positive trends in at least one domain, favouring pharmacist-led or pharmacist-involved care over usual care.

Conclusion: Pharmacist-led interventions in outpatient mental health settings are associated with positive clinical and healthcare-related outcomes across a range of mental disorders globally. These findings support the integration of pharmacists into multidisciplinary outpatient mental health teams and highlight the need for more high-quality, standardised research to inform service development and policy.

评估药剂师在门诊精神卫生设置的影响:一个系统的回顾。
导言:据估计,全球七分之一的人受到精神障碍的影响,并且往往与过早死亡有关。精神药物在许多精神健康状况的管理中发挥重要作用,特别是在症状中度至重度、持续性或复杂的情况下。药剂师越来越被认为是多学科精神卫生团队的关键成员,他们的作用侧重于安全有效地使用精神药物。精神保健越来越多地在门诊环境中提供,然而,药剂师对这些服务的影响仍未得到充分探讨。目的:系统地回顾和评估药剂师主导或药剂师参与的干预措施的影响,特别是在门诊精神卫生机构中,在全球范围内,跨越精神障碍的全谱。方法:系统检索MEDLINE、Embase、CINAHL、CENTRAL、PsycINFO 5个电子数据库,检索时间为建库至2025年10月。灰色文献来源包括ClinicalTrials.gov和谷歌Scholar。纳入标准为:(i)评估药剂师主导或药剂师参与的干预措施的可测量结果;(ii)在门诊精神卫生机构进行,涉及根据ICD(达到并包括ICD-11)或DSM标准(达到并包括DSM-5)诊断为精神障碍的成年人,不包括痴呆症;(iii)纳入比较国或对照组。研究筛选、数据提取和质量评价由两名审稿人独立完成。由于研究设计和结果的异质性,我们进行了叙事综合。结果:23项研究符合纳入标准:11项随机对照试验和12项非随机研究。药剂师的干预措施多种多样,但最常见的包括药物审查、心理教育、依从性支持和副作用或药物相互作用的监测。结果分为七个领域:患者报告、症状相关、治疗相关、药物依从性、成本、监测和住院。药剂师的影响与多个领域的改善有关,特别是在药物依从性、治疗相关和症状相关的结果方面。虽然不同研究的结果不同,但大多数(82.6%)报告了至少一个领域的积极趋势,与常规护理相比,更倾向于药剂师主导或药剂师参与的护理。结论:在门诊精神卫生机构中,药剂师主导的干预措施与全球范围内一系列精神障碍的积极临床和卫生保健相关结果相关。这些发现支持将药剂师纳入多学科门诊精神卫生团队,并强调需要更多高质量、标准化的研究,以便为服务发展和政策提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
8.30%
发文量
131
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences. IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy. IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor. International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy . Until 2010 the journal was called Pharmacy World & Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书